Krystal Biotech (KRYS) Convertible Debt (2016)

Krystal Biotech (KRYS) posted quarterly Convertible Debt of $1.1 million for Q4 2016.

Krystal Biotech (KRYS) Convertible Debt (2016) Analysis & Trends

Krystal Biotech has reported Convertible Debt for 1 years, with the latest figure at $1.1 million in Q4 2016.

Convertible Debt for Q4 2016 came in at $1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was $1.1 million (changed N/A YoY), and the FY2016 annual result was $1.1 million, changed N/A from the prior year.
Convertible Debt held at $1.1 million in Q4 2016.
Over five years, Convertible Debt peaked at $1.1 million in Q4 2016 and troughed at $1.1 million in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Krystal Biotech	9.83 Bn	8.99 Bn	112.79 Mn

Historic Data

Download Data

Date	Value
Dec 31, 2016	1.15 Mn